



## An ASA a day when a baby's on the way?

### CLINICAL QUESTION

**Is acetylsalicylic acid (ASA) effective in preventing complications in pregnant women at risk of preeclampsia?**

### BOTTOM LINE

**In women at risk for preeclampsia at ~12-28 weeks gestation, low-dose ASA (50-150mg) reduces risk of preeclampsia by an absolute ~2%, perinatal death by ~0.5%, and preterm birth by ~2% compared to placebo. The risk of postpartum hemorrhage is increased by up to ~1%.**

### EVIDENCE

- 7 systematic reviews (17-77 randomized controlled trials [RCTs]; 26,952-46,568 patients) from the last 5 years comparing ASA to placebo in pregnant women at varying preeclampsia risk.<sup>1-7</sup> ASA usually initiated ~12-28 weeks, continued until delivery. Results statistically significant unless indicated.
  - Maternal Outcomes:
    - Preeclampsia: 5 systematic reviews (16-60 RCTs):<sup>1-5</sup>
      - 4.5-9.6% versus 5.8-11.8% (placebo), number needed to treat (NNT)=31-72.
    - Placental abruption: 3 systematic reviews (9-29 RCTs):<sup>1,3,4</sup>
      - 0.9-1.3% versus 0.7-1.2% (placebo) (not statistically different).
    - Postpartum hemorrhage (>500-1000mL blood loss): 4 systematic reviews (9-19 RCTs):<sup>1,3,4,6</sup>

- 3.7-15.2% versus 3.3-14.3% (placebo), number needed to harm (NNH)=97-239 (1/4 systematic reviews not statistically different).<sup>4</sup>
- Fetal outcomes:
  - Perinatal death: 3 systematic reviews (11-52 RCTs):<sup>1,3,4</sup>
    - 2.1-3.1% versus 2.7-3.5% (placebo), NNT=179-239.
  - Preterm delivery/birth: 2 systematic reviews with comprehensive data (18-47 RCTs):<sup>1,3</sup>
    - 15.9-16.6% versus 17.5-18.5% (placebo), NNT=54-64.
  - Fetal intracranial bleed: 1 systematic review (6 RCTs):<sup>4</sup>
    - Not statistically different.
- Limitations: Inconsistent definitions of patients at risk for preeclampsia; infrequent reporting of serious maternal outcomes (examples: eclampsia, death); some large RCTs not included in all systematic reviews.

## CONTEXT

- No clear difference in outcomes between 50-150 mg daily.<sup>1,3-5,7</sup>
- Earlier initiation (<16-20 weeks) may enhance preeclampsia benefit based on subgroup analyses. No consistent trends for other outcomes.<sup>1-4,7</sup>
- Sensitivity of clinical risk factors for predicting pre-eclampsia is <40%.<sup>8</sup>
- Guidelines vary:
  - Common recommendations among guidelines for ASA use include, but not limited to:
    - Any high-risk factors (examples: prior preeclampsia, chronic hypertension, renal or autoimmune disease, diabetes) or,
    - At least 2 moderate-risk factors (examples: nulliparity, age >35-40, previous adverse pregnancy outcome).
  - Canadian: ASA 81-162mg daily preferably before 16 weeks until 36 weeks gestation.<sup>8</sup>
  - American: ASA 81mg daily initiated between 12-28 weeks gestation (optimally before 16 weeks) until delivery.<sup>9</sup>

## REFERENCES

1. Duley L, Meher S, Hunter KE, *et al.* Cochrane Database Syst Rev. 2019: CD004659.
2. Wang Y, Guo X, Obore N, *et al.* Front Cardiovasc Med. 2022; 9:936560.
3. Choi YJ, Shin S. Am J Prev Med. 2021; 61(1):e31-e45.
4. Henderson JT, Vesco KK, Senger CA, *et al.* JAMA. 2021; 326(12):1192-1206.
5. van Doorn R, Mukhtarova N, Flyke IP, *et al.* PLoS One. 2021; 16(3):e0247782.
6. Jiang Y, Chen Z, Chen Y, *et al.* Am J Obstet Gynecol MFM 2023; 5:100878.
7. Turner JM, Robertson NT, Hartel G, *et al.* Ultrasound Obstet Gynecol. 2020; 55(2):157-169.

## AUTHORS

**Brianne Desrochers**, PharmD candidate, **Sasha Katwaroo**, PharmD candidate, **Karen Toews** MD CCFP, **Jamie Falk** PharmD

*Authors do not have any conflicts of interest to declare.*

8. Magee LA, Smith GN, Bloch C, *et al.* J Obstet Gynaecol Can. 2022; 44(5):547-571.e1.
9. ACOG Committee. Obstet Gynecol. 2018; 132(1):254-256.

---

**TOOLS FOR PRACTICE  
PROVIDED BY**



---

**IN PARTNERSHIP WITH**



**Tools for Practice** are peer reviewed and summarize practice-changing medical evidence for primary care. Coordinated by **Dr. G. Michael Allan** and **Dr. Adrienne Lindblad**, they are developed by the Patients, Experience, Evidence, Research (PEER) team, and supported by the College of Family Physicians of Canada, and the Alberta, Ontario, and Saskatchewan Colleges of Family Physicians. Feedback is welcome and can be sent to [toolsforpractice@cfpc.ca](mailto:toolsforpractice@cfpc.ca). Archived articles can be found at [www.toolsforpractice.ca](http://www.toolsforpractice.ca)

*This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the College of Family Physicians of Canada.*